Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 7/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | GHSR | Q92847 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2571339 | 0.90 | PTGDR2 (0.50) | PTGDR2RORCCHRM1EGLN1GHSR | |
| SCHEMBL2573441 | 0.85 | PTGDR2 (0.46) | PTGDR2RORCCHRM1SCN9AEGLN1 | |
| SCHEMBL2571350 | 0.85 | PTGDR2 (0.43) | PTGDR2RORCGHSRJAK2 | |
| SCHEMBL27801736 | 0.85 | RORC (0.38) | PTGDR2RORCCHRM1SCN9A | |
| SCHEMBL3772138 | 0.84 | ALDH1A1 (0.41) | JAK2 | |
| SCHEMBL3778704 | 0.84 | LMNA (0.38) | PTGDR2 | |
| SCHEMBL3351455 | 0.84 | PTGDR2 (0.43) | PTGDR2RORCCHRM1SCN9AKLKB1 | |
| SCHEMBL2573787 | 0.82 | RORC (0.42) | PTGDR2RORCCHRM1SCN9A | |
| SCHEMBL2568427 | 0.82 | RORC (0.48) | PTGDR2RORC | |
| SCHEMBL2574623 | 0.81 | PTGDR2 (0.46) | PTGDR2RORCSCN9AKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394830-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| US-20120184579-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2012-07-19 | — | — | US | disclosed |
| US-8173812-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| EP-2139881-B1 | QUINOLINES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2011-11-09 | — | — | EP | disclosed |
| US-20100144787-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2010-06-10 | — | — | US | disclosed |
| WO-2010040989-A1 | QUINOLIN-2-ONE COMPOUNDS | ARGENTA ORAL THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | WO | disclosed |
| EP-2139881-A1 | QUINOLINES AND THEIR THERAPEUTIC USE | Argenta Oral Therapeutics Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008122784-A1 | QUINOLINES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144787-A1 | Quinolines and Their Therapeutic Use | CHRM3, CHRM2, HRH1 | PTGDR2 301/4885RORC 111/4885CHRM1 5/4885 |
| US-20120184579-A1 | Quinolines and Their Therapeutic Use | HRH1, CHRM2, CHRM3 | PTGDR2 316/4885RORC 118/4885CHRM1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.